$5.41
0.37% yesterday
Nasdaq, Aug 01, 10:00 pm CET
ISIN
NL0015436031
Symbol
CVAC

CureVac N.V. Stock price

$5.41
+0.00 0.00% 1M
+1.86 52.39% 6M
+2.00 58.65% YTD
+1.83 51.12% 1Y
-7.51 58.13% 3Y
-50.49 90.32% 5Y
-50.49 90.32% 10Y
-50.49 90.32% 20Y
Nasdaq, Closing price Fri, Aug 01 2025
+0.02 0.37%
ISIN
NL0015436031
Symbol
CVAC
Industry

Key metrics

Basic
Market capitalization
$1.2b
Enterprise Value
$751.6m
Net debt
positive
Cash
$512.5m
Shares outstanding
225.2m
Valuation (TTM | estimate)
P/E
5.9 | negative
P/S
2.0 | 15.1
EV/Sales
1.3 | 9.4
EV/FCF
4.6
P/B
1.6
Financial Health
Equity Ratio
86.8%
Return on Equity
23.3%
ROCE
28.8%
ROIC
69.5%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$607.2m | $80.4m
EBITDA
$250.9m | $-100.0m
EBIT
$227.5m | $-126.4m
Net Income
$209.4m | $-123.6m
Free Cash Flow
$166.0m
Growth (TTM | estimate)
Revenue
787.5% | -86.8%
EBITDA
180.2% | -144.4%
EBIT
167.3% | -162.3%
Net Income
166.1% | -166.8%
Free Cash Flow
145.9%
Margin (TTM | estimate)
Gross
87.6%
EBITDA
41.3% | -124.4%
EBIT
37.5%
Net
34.5% | -153.8%
Free Cash Flow
27.3%
More
EPS
$0.9
FCF per Share
$0.7
Short interest
0.9%
Employees
904
Rev per Employee
$680.0k
Show more

Is CureVac N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,028 stocks worldwide.

CureVac N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a CureVac N.V. forecast:

6x Buy
46%
7x Hold
54%

Analyst Opinions

13 Analysts have issued a CureVac N.V. forecast:

Buy
46%
Hold
54%

Financial data from CureVac N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
607 607
788% 788%
100%
- Direct Costs 75 75
55% 55%
12%
532 532
631% 631%
88%
- Selling and Administrative Expenses 74 74
19% 19%
12%
- Research and Development Expense 174 174
36% 36%
29%
251 251
180% 180%
41%
- Depreciation and Amortization 23 23
7% 7%
4%
EBIT (Operating Income) EBIT 228 228
167% 167%
37%
Net Profit 209 209
166% 166%
34%

In millions USD.

Don't miss a Thing! We will send you all news about CureVac N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CureVac N.V. Stock News

Neutral
Accesswire
about one month ago
TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / June 24, 2025 / CureVac N.V. (NASDAQ:CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today announced the voting results of the Company's Annual General Meeting.
AD HOC NEWS
about one month ago
CureVac / NL0015436031
AD HOC NEWS
about one month ago
CureVac / NL0015436031
More CureVac N.V. News

Company Profile

CureVac BV is a clinical-stage biopharmaceutical Company developing tumour immunotherapy. It offers RNA optimization that encode functional proteins that replace defective or missing proteins using the cell's intrinsic translation machinery. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Head office Netherlands
CEO Alexander Zehnder
Employees 904
Founded 2020
Website www.curevac.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today